Ever remember a time when everything you touched turned to gold? Like Starbucks during the 1990s, Apple since it discovered the iPod, or Google since it became Google. It's like some companies get in a "zone" where they just can't miss.

CVS Caremark (NYSE:CVS) has been in that "zone" ever since CVS tied the knot with Caremark last year. The synergies between selling prescriptions, helping customers manage their benefits, and getting a few extra items thrown in the shopping cart are looking more and more irresistable.

The company proved once again it's no sicko by posting third-quarter sales that increased 83% compared to last year, to $20.5 billion. Comparable-store sales were up 5%, with the script business contributing 4.3%, and the front end adding 6.5%. Operating margins expanded 140 basis points. Gross margins in the PBM segment were up 130 b.p. and increased 160 b.p. in the retail segment. Diluted earnings per share jumped 37% to $0.45, beating Street expectations by a penny.

CVS has been on a roll over the past nine months, with sales up 71% and earnnigs per share up 22%. Investors have noticed the stellar performance and have boosted the stock 25% higher since the beginning of the year.

In the conference call, president and CEO Tom Ryan described it as a "measured, evolutionary process that will continue to pick up steam in '08 and beyond." The company is adding Minute Clinics into the retail stores as fast as it can. Since last quarter, CVS has contracted an additional $600 million in new businesses for 2008, a combination of PBM and Medicare Part D. Even the Save-on and Osco stores acquired from Albertsons last year are showing sales and margin improvements.

It's not like competitors aren't trying to take a share of this market. Wal-Mart (NYSE:WMT) continues to lower prescription prices, and Walgreen (NYSE:WAG) is building stores like crazy. But I think CVS has a competitive advantage in the number and quality of "touch-points" it has with the prescription-consuming customer. As long as CVS can provide the best service to this rapidly growing customer base, it appears unstoppable in the near term.

Catch up on the pharmacy market with:

Fool contributor Timothy M. Otte surveys the retail scene from Dallas. He welcomes comments on his articles, and owns shares of Wal-Mart, but none of the other companies mentioned in this article. Wal-Mart is an Inside Value pick. The Fool has a disclosure policy.